Compare Pfizer Inc (PFE) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs RLX Technology Inc — how do they compare? Pfizer Inc trades at $27.72 (market cap $158.56B), while RLX Technology Inc trades at $1.72 (market cap $2.10B). The key difference: Pfizer Inc is far larger — about 75.5× RLX Technology Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and RLX Technology Inc for 34 Days on average.
| PFE | RLX | |
|---|---|---|
Market Cap | $158.56B | $2.10B |
Volume | 44,138,282 | 1,079,706 |
Sector | Health | Consumer Staples |
52-Week High | $29.02 | $2.57 |
52-Week Low | $23.67 | $1.68 |
Typical Hold Time | 158 Days | 34 Days |
Enterprise Value | $210.06B | $832.26M |
Dividend Yield | 6.18% | 5.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
RLX Technology trades at $1.73, near its 52-week low of $1.67, with bearish technical signals from moving averages. The company reported strong 2025 fundamentals with $921.87M net income and 21.87% net margin, though recent quarters show earnings misses. International expansion drives growth, with 70% of revenue now from overseas markets following European acquisitions.
The stock presents a value opportunity with discounted valuation multiples (P/E 15.46, P/B 0.91) but faces headwinds from recent earnings underperformance and bearish technical momentum. Key risks include margin compression and regulatory uncertainty in the e-vapor industry, while analyst sentiment remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
